Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Epacadostat||INCB024360|INCB 024360|INCB-024360||IDO1 Inhibitor 10 Immune Checkpoint Inhibitor 94||Epacadostat (INCB024360) inhibits indoleamine 2,3-dioxygenase 1 (IDO1) to prevent tryptophan breakdown in the tumor microenvironment, thereby activating a cytotoxic immune response against IDO1 expressing tumor cells (PMID: 20197554, PMID: 32564277).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Epacadostat||Phase I||Actionable||In a Phase I trial, treatment with Epacadostat resulted in stable disease in 13% (7/52) of patients with advanced solid tumors for greater than or equal to 16 weeks, including two patients with melanoma who previously failed on immunotherapy (PMID: 28053021).||28053021|
|Unknown unknown||Advanced Solid Tumor||not applicable||Epacadostat||Phase I||Actionable||In a Phase I trial, treatment with Epacadostat resulted in stable disease in 13% (7/52) of patients with advanced solid tumors for greater than or equal to 16 weeks, including two patients with melanoma who previously failed on immunotherapy (PMID: 28053021).||28053021|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02575807||Phase Ib/II||Epacadostat CRS-207||Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer||Terminated|
|NCT03516708||Phase Ib/II||Pembrolizumab Epacadostat Capecitabine + Oxaliplatin||Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer||Recruiting|
|NCT02118285||Phase I||Aldesleukin Epacadostat Cyclophosphamide Fludarabine||Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||Completed|
|NCT03471286||Phase I||Epacadostat||A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies||Recruiting|
|NCT02166905||Phase Ib/II||Poly ICLC Rasdegafusp alfa Epacadostat||DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission||Active, not recruiting|
|NCT02042430||Phase I||Epacadostat||INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer||Active, not recruiting|
|NCT01961115||Phase II||Epacadostat MELITAC 12.1 Peptide Vaccine||INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma||Completed|